Novartis experienced significant intraday upward movement, driven primarily by favorable clinical trial data and regulatory advancements for its key pharmaceutical assets.

A major catalyst was the release of final Phase III ALIGN study results for Vanrafia, a treatment for IgA nephropathy. The data, published in The Lancet and presented at the European Renal Association Congress, indicated a substantial reduction in the decline of kidney function and improvements in protein levels. These positive outcomes support the company’s efforts to secure traditional regulatory approvals for Vanrafia, following its accelerated approval in the United States and China in 2025. This development is seen as a significant step forward in addressing a…